Private Equity Investors
Diligence and structuring at deal speed, with sector depth in hand.
Your diligence window is finite, the information advantage decays fast, and the competition for quality healthcare and pharma assets in the GCC is real. What the mandate needs is a buy-side advisor who is deployable now, with sector depth already in hand, not a team being assembled for the first time after the clock has started. Generalist advisors can run financial diligence in most sectors. GCC healthcare is not most sectors, and what they do not know about it is exactly the risk that reprices the deal after close.
What you engage us for
You engage Avior for integrated commercial, regulatory, and operational diligence on healthcare and pharma targets. The regulatory architecture (DHA in Dubai, DOH in Abu Dhabi, MOHAP at federal level, plus emirate-specific licensing) determines what the asset can do, what it would cost to fix, and whether the operational risk is priceable. Payer mix, physician-ownership restrictions, licensing portability, and staffing ratios create value and risk at once; standard EBITDA normalisation does not capture them. We also build the exit story before the process starts, and provide CFO-level support through a transition.
How we work
The principal delivers the diligence, the operational work, and the exit preparation. Not a team brought together for this engagement: a principal who has done this work before and carries the full analytical burden, at the speed your mandate runs. Post-close, we work the value-creation plan at the asset level, where clinical efficiency, procurement, and back-office consolidation separate what is achievable from what only looked good in the CIM.
Speed without depth is not an advantage. We hold both.